Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

People In The News – Tracking The Latest Industry Personnel Moves

  • News

Executive Summary

Presidents And CEOs

You may also be interested in...



Antigen Express Takes Independence For A Spin, Hopes To Move Cancer Vaccine Forward

Executives at cancer vaccine developer Antigen Express will soon find out whether independence can pave the road to success in the financing arena.

Execs On The Move, January 2023: Spun-Off GE Healthcare Names Board, Officers

An interactive view of medtech executive changes from the month of January 2023, including GE Healthcare's new leadership as a standalone company.

Axogen, Dario Health, Biobeat, Immunexpress All Weigh In On 2022 And What Will Succeed In 2023

Medtech Insight was invited to ask questions at a roundtable event organized by Russo Partners to review the major medtech industry trends of 2022 and what to expect in 2023.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

EU Regulators May Check Redactions In CTIS Documents To Boost Trial Transparency

Next UK Drug Pricing Scheme Needs ‘Single-Digit Fixed Rebates’

Pharmacies Likely To Cease Prescribing COVID-19 Therapeutics With End Of Public Health Emergency

The IRA And US FDA: How Will Agency View Any Drug Development Changes?

See All
UsernamePublicRestriction

Register

PS053560

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By